Om du vill rapportera en biverkning gällande en av Lillys produkter, kontakta oss via e-post på DK_PHv@lilly.com eller på telefon +45 4526 6040. Har du ytterligare medicinska frågor gällande en av Lillys produkter, kontakta oss via länken ovan.
Taltz ® (ixekizumab) injektion
Denna information är endast avsedd för sjukvårdspersonal verksam i Sverige och som svar på din fråga. Informationen nedan är på engelska
No head-to-head trials have been conducted comparing the efficacy and safety of ixekizumab to that of tildrakizumab in the treatment of psoriasis.
Ixekizumab is an IgG4 monoclonal antibody that binds with high affinity (< 3 pM) and specificity to interleukin 17A (both IL‑17A and IL‑17A/F). Elevated concentrations of IL‑17A have been implicated in the pathogenesis of psoriasis by promoting keratinocyte proliferation and activation, as well as in the pathogenesis of psoriatic arthritis and axial spondyloarthritis by driving inflammation leading to erosive bone damage and pathological new bone formation. Neutralisation of IL‑17A by ixekizumab inhibits these actions. Ixekizumab does not bind to ligands IL‑17B, IL‑17C, IL‑17D, IL‑17E or IL‑17F.1
In vitro binding assays confirmed that ixekizumab does not bind to human Fcγ receptors I, IIa, and IIIa or to complement component C1q.1
Tildrakizumab-asmn is a humanized IgG1/k mAb that selectively binds to the p19 subunit of IL-23 and inhibits its interaction with the IL-23 receptor. IL-23 is a naturally occurring cytokine that is involved in inflammatory and immune responses. Tildrakizumab inhibits the release of proinflammatory cytokines and chemokines.2
Since clinical trials are conducted under widely varying and controlled conditions, efficacy outcomes and adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
Adjusted Indirect Comparison of Ixekizumab and Tildrakizumab in Plaque Psoriasis
The methodology used to indirectly compare the efficacy outcomes (PASI 75, PASI 90, and PASI 100) of ixekizumab and tildrakizumab in patients with moderate-to-severe psoriasis were
AIC using the Bucher method, and
MAIC using the Signorovitch method in which reweighting was performed matching the following baseline characteristics in terms of means or percentages: patient age, sex, previous biologic treatment, PASI score, and BSA affected.3
Both methods of indirect comparisons used are subject to limitations including the potential for bias due to differences between trial populations and imbalances in unobserved factors between trials. These limitations can only be avoided with head-to-head randomized trials.4,5
Figure 1. Study Design for Indirect Comparison of Ixekizumab and Tildrakizumab3
Abbreviations: ETN = etanercept; IXE = ixekizumab; PASI 75/90/100 = 75%/90%/100% improvement from baseline in Psoriasis Area and Severity Index; PBO = placebo; TIL = tildrakizumab.
Dashed line represents indirect comparison and solid line represents direct comparison.
The risk differences for PASI responses up to week 12 are available in Figure 2.
The authors concluded the results of this indirect comparison suggest that ixekizumab might provide clinical benefits over tildrakizumab in terms of faster onset of action and higher levels of skin clearance up to week 12 in patients with moderate-to-severe psoriasis.3
Figure 2. Ixekizumab vs Tildrakizumab Indirect Comparison of PASI Responses Via Comparator Bridges3
Abbreviations: AIC = adjusted indirect comparison; ETN = etanercept; IXE = ixekizumab; MAIC = matching adjusted indirect comparison; PASI = Psoriasis Area Severity Index; PASI 75/90/100 = 75%/90%/100% improvement from baseline in Psoriasis Area and Severity Index; PBO = placebo; TIL = tildrakizumab.
3. Gottlieb A, Saure D, Wilhelm S, et al. Indirect comparison of ixekizumab versus tildrakizumab for up to 12 weeks of treatment in patients with moderate-to-severe psoriasis. Poster presented at: 77th Annual Meeting of the American Academy of Dermatology; March 1-5, 2019; Washington, D.C. https://www.aad.org/eposters/Submissions/getFile.aspx?id=8051&type=sub
4. Bucher HC, Guyatt GH, Griffith LE, et al. The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials. J Clin Epidemiol 1997;50(6):683-691. https://doi.org/10.1016/S0895-4356(97)00049-8
5. Signorovitch JE, Wu EQ, Yu AP, et al. Comparative effectiveness without head-to-head trials: a method for matching-adjusted indirect comparisons applied to psoriasis treatment with adalimumab or etanercept. Pharmacoeconomics. 2010;28(10):935-945. http://dx.doi.org/10.2165/11538370-000000000-00000
AIC = adjusted indirect comparison
BSA = body surface area
IgG1 = immunoglobulin G subclass 1
IgG4 = immunoglobulin G subclass 4
IL = interleukin
mAb(s) = monoclonal antibody
MAIC = matched-adjusted indirect comparison
PASI = Psoriasis Area and Severity Index
PASI 75 = 75% improvement from baseline in Psoriasis Area and Severity Index
PASI 90 = 90% improvement from baseline in Psoriasis Area and Severity Index
PASI 100 = 100% improvement from baseline in Psoriasis Area and Severity Index
Datum fӧr senaste ӧversyn 2019 M08 19